Αποτελέσματα Αναζήτησης
15 Μαρ 2021 · Prazosin is an FDA-approved medication for high blood pressure that may also help reduce alcohol cravings and relapse risk. Learn how it works, who may benefit from it, and what research shows about its effectiveness.
4 Δεκ 2023 · New research finds that semaglutide, the active ingredient in GLP-1 drugs like Ozempic and Wegovy, may significantly reduce alcohol cravings.
Neuroscientific advances have led to identification of novel therapeutic targets and development of new medications in this regard . The goal of this paper is to provide an update on medication development efforts for AUD by reviewing human studies published in the past two years. ... Morley KC, et al. , Baclofen in the treatment of alcohol ...
13 Μαρ 2024 · Published in the June 2023 issue of the journal JCI Insight, the study adds to growing preclinical evidence that the glucagon-like peptide-1 (GLP-1) system plays a role in alcohol and other substance use disorders, and that GLP-1 receptor agonists show potential for treating people with alcohol use disorder (AUD).
20 Μαΐ 2020 · The FDA has approved three medications for alcohol use disorder: naltrexone, acamprosate, and disulfiram. Additionally, other medications including gabapentin, baclofen, topiramate, and ondansetron show promise off-label for treating alcohol use disorder.
30 Ιουλ 2021 · The therapy targets the enzyme mTORC1 in the brain, which is involved in memory and addiction, and blocks its activity with a second molecule that does not cross the blood-brain barrier. The approach shows promise in mice and may apply to other drugs of abuse.
In this systematic review and meta-analysis that included 118 clinical trials, the highest strength of evidence for treatment of alcohol use disorder was available for acamprosate and oral naltrexone (50 mg/d).
